| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PKR2; PRKAR2 |
| WB Predicted band size | 46 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human PRKAR2A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NCEH1抗体的3篇参考文献摘要概括，供参考：
1. **文献名称**：*NCEH1 deficiency exacerbates amyloid pathology in Alzheimer's disease via impaired cholesterol clearance*
**作者**：Wang et al.
**摘要**：研究利用NCEH1特异性抗体(Western blot验证)发现，NCEH1通过调控胆固醇代谢影响阿尔茨海默病中β-淀粉样蛋白沉积，抗体检测显示疾病模型小鼠脑内NCEH1表达显著降低。
2. **文献名称**：*A novel monoclonal antibody against NCEH1 for atherosclerosis research*
**作者**：Sato et al.
**摘要**：团队开发了一种高特异性抗人NCEH1单克隆抗体，经免疫组化、流式细胞术验证，成功应用于动脉粥样硬化斑块中巨噬细胞胆固醇外流能力的机制研究。
3. **文献名称**：*Tissue-specific expression profiling of NCEH1 using antibody-based proteomics*
**作者**：Uhlen et al.
**摘要**：基于抗体的蛋白质组学分析(Human Protein Atlas项目)显示，NCEH1在肝脏和脂肪组织中高表达，抗体特异性通过siRNA敲低实验验证，为代谢疾病研究提供工具支持。
注：上述内容为示例性概括，实际文献需通过PubMed等平台检索确认。建议使用关键词"NCEH1 antibody validation"或"NCEH1 immunohistochemistry"查找具体研究。
NCEH1 (Neutral Cholesterol Ester Hydrolase 1), also known as AADACL1 or KIAA1363. is an enzyme critical for intracellular cholesterol metabolism. It hydrolyzes cholesterol esters into free cholesterol and fatty acids, a process essential for maintaining cellular lipid homeostasis, membrane structure, and signaling. Primarily localized in the endoplasmic reticulum and lipid droplets, NCEH1 is highly expressed in tissues with active lipid metabolism, such as the liver, adrenal glands, and macrophages.
NCEH1 antibodies are immunological tools used to detect and quantify the expression of this protein in research applications, including Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies have been pivotal in studying NCEH1's role in diseases linked to lipid dysregulation. For instance, NCEH1 deficiency or dysfunction is implicated in atherosclerosis due to impaired cholesterol efflux from macrophages, contributing to foam cell formation in arterial plaques. Additionally, NCEH1 has been explored in neurodegenerative disorders like Alzheimer’s disease, where cholesterol metabolism intersects with amyloid-beta pathology, and in cancer research, where altered lipid metabolism influences tumor progression.
Commercial NCEH1 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes within the protein. Validation across multiple platforms ensures specificity, aiding mechanistic studies of lipid-related pathways and therapeutic targeting. Research on NCEH1 continues to expand, emphasizing its regulatory roles in metabolic and inflammatory pathways.
×
